VEGF Spliced Variants: Possible Role of Anti-Angiogenesis Therapy

di Hilmi, Caroline, Guyot, Mélanie, Pagès, Gilles
Pubblicazione 2012

The ELR(+)CXCL chemokines and their receptors CXCR1/CXCR2: A signaling axis and new target for the treatment of renal cell carcinoma

di Giuliano, Sandy, Guyot, Mélanie, Grépin, Renaud, Pagès, Gilles
Pubblicazione 2014

Targeting the pro-angiogenic forms of VEGF or inhibiting their expression as anti-cancer strategies

di Guyot, Mélanie, Hilmi, Caroline, Ambrosetti, Damien, Merlano, Marco, Nigro, Cristiana Lo, Durivault, Jérôme, Grépin, Renaud, Pagès, Gilles
Pubblicato in Oncotarget (2016)

The combination of bevacizumab/Avastin and erlotinib/Tarceva is relevant for the treatment of metastatic renal cell carcinoma: the role of a synonymous mutation of the EGFR recepto...

di Grépin, Renaud, Guyot, Mélanie, Dumond, Aurore, Durivault, Jérôme, Ambrosetti, Damien, Roussel, Jean-François, Dupré, Florence, Quintens, Hervé, Pagès, Gilles
Pubblicato in Theranostics (2020)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

di Dufies, Maeva, Giuliano, Sandy, Viotti, Julien, Borchiellini, Delphine, Cooley, Linsay S, Ambrosetti, Damien, Guyot, Mélanie, Ndiaye, Papa Diogop, Parola, Julien, Claren, Audrey, Schiappa, Renaud, Gal, Jocelyn, Frangeul, Antoine, Jacquel, Arnaud, Cassuto, Ophélie, Grépin, Renaud, Auberger, Patrick, Bikfalvi, Andréas, Milano, Gérard, Escudier, Bernard, Rioux-Leclercq, Nathalie, Porta, Camillo, Negrier, Sylvie, Chamorey, Emmanuel, Ferrero, Jean-Marc, Pagès, Gilles
Pubblicato in Br J Cancer (2017)